It's good news for Migraine patients as Eli Lilly and Company's Emgality™ (galcanezumab-gnlm) became the third new CGRP monoclonal antibody approved by the FDA for Migraine Prevention in Adults. With Emgality™ approved for Migraine prevention, patients have choices of preventive treatments were developed specifically for Migraine.
NIH awards grant to CerSci Therapeutics for a preclinical trial to explore the development of a potentially new Migraine treatment blocking the free radical, peroxynitrite. This is just the first of many new studies we can expect as researchers work to develop better, safer treatments for Migraine.
Everyone feels anxious on occasion. It's a normal, healthy emotion that alerts us to possible threats. It's only problematic when our natural alarm sounds during otherwise safe situations. Anxiety is one of several associated symptoms of a Migraine attack. After all, the pain and emotion pathways in the brain are closely linked.
Ten percent of all U.S. students under the age of 18 have migraine. Based on average class size of 15 students, that's 1-2 students in every classroom. The tightly-packed schedules, over-crowded classrooms, and sensory overload creates an unfriendly environment for children with migraine. Students with migraine deserve better.
This is a transcript of an interview with Dr. Peter Goadsby. I had the privilege of meeting with him in San Francisco at the June 2018 AHS Scientific Meeting. In the interview, we discussed the recent results of the Autonomic Technologies CH-2 clinical trial of their sphenopalatine ganglion microstimulator system.